Article
Chemistry, Medicinal
Hannah M. King, Sandeep Rana, Sydney P. Kubica, Jayapal Reddy Mallareddy, Smitha Kizhake, Edward L. Ezell, Muhammad Zahid, Michael J. Naldrett, Sophie Alvarez, Henry C-H Law, Nicholas T. Woods, Amarnath Natarajan
Summary: CDK9, a member of the cyclin-dependent kinase family, is involved in transcriptional regulation. Researchers developed PROTAC 2, a compound that selectively degrades CDK9, sensitizing cells to growth inhibition by Venetoclax.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Oncology
Mohaddase Hamidi, Ainhoa Eriz, Jone Mitxelena, Larraitz Fernandez-Ares, Igor Aurrekoetxea, Patricia Aspichueta, Ainhoa Iglesias-Ara, Ana M. Zubiaga
Summary: The study reveals that inhibiting E2F activity in prostate cancer cells can increase sensitivity to drug-induced replication stress and cell death. Furthermore, inhibiting E2F can also reduce the growth capacity of cancer cells when combined with drugs targeting nucleotide biosynthesis or DNA repair, suggesting a promising strategy for prostate cancer treatment.
Article
Immunology
Fei Ding, Xi Luo, Yiting Tu, Xianlan Duan, Jia Liu, Lijing Jia, Peilin Zheng
Summary: The findings suggest that Alpk1 plays a crucial role in cytokine-induced beta cell apoptosis and its activation can exacerbate cytokine-induced apoptosis by potentiating the TNF-α signaling pathway. Additionally, Alpk1 activation may further induce the expression of proteins such as TNF-α and Fas, contributing to beta cell failure and T1D development. Treatment with GLP-1 receptor agonist could decrease TNF-α and Fas expression, improving the survival of beta cells exposed to pro-inflammatory cytokines and ADP heptose.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yu Ren, Xue Wang, Shuaishuai Huang, Yangkai Xu, Guobin Weng, Rui Yu
Summary: In this study, we found that alternol sensitized renal carcinoma cells to TRAIL-induced apoptosis by inhibiting antiapoptotic proteins, upregulating DR5 levels, ROS generation, and the CHOP pathway, thus enhancing TRAIL-mediated apoptosis.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Jason M. Biegel, Mayura Dhamdhere, Shuang Gao, Chethana P. Gowda, Yuka Imamura Kawasawa, Vladimir S. Spiegelman
Summary: The gain at chromosome 17q21 in neuroblastoma is associated with poor prognosis regardless of MYCN amplification status. Down-regulation of IGF2BP1 activity suppresses neuroblastoma cell growth, and combining IGF2BP1 inhibition with chemotherapeutics or CDK inhibitors has a synergistic effect on suppressing neuroblastoma cell proliferation.
FRONTIERS IN ONCOLOGY
(2021)
Article
Food Science & Technology
Jinkyung Lee, Chan Ho Jang, Yoonsu Kim, Jisun Oh, Jong-Sang Kim
Summary: This study examined the ability of quercetin to sensitize colorectal cancer cells to oxaliplatin by inhibiting glutathione reductase activity. The combination of quercetin and oxaliplatin was found to synergistically inhibit glutathione reductase activity, reduce cell viability, and increase reactive oxygen species production. Addition of sulforaphane further enhanced the anti-cancer efficacy of this combination therapy in a mouse model.
Article
Medical Laboratory Technology
Zhenfeng Tian, Ying Tan, Xingyi Lin, Mingxin Su, Lele Pan, Lijun Lin, Guangsheng Ou, Yinting Chen
Summary: TIMP1 and p-mTOR are elevated in pancreatic ductal adenocarcinoma (PDAC) patients and are associated with worse overall survival. The TIMP1/PI3K/AKT/mTOR pathway is involved in epithelial-mesenchymal transition and apoptosis, and can be suppressed by the combination of ATO and GEM, leading to sensitization and reversal of GEM resistance. The combination therapy has synergistic anticancer effects in vitro and in vivo.
TRANSLATIONAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Manami Semba, Shinji Takamatsu, Sachiko Komazawa-Sakon, Eiji Miyoshi, Chiharu Nishiyama, Hiroyasu Nakano, Kenta Moriwaki
Summary: The study identified proscillaridin A as a promising agent that enhances the anti-cancer efficacy of TRAIL therapeutics, particularly in colon cancer cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Dermatology
Zizhen Ming, Su Yin Lim, Ashleigh Stewart, Bernadette Pedersen, Elena Shklovskaya, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Jenny H. Lee, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Summary: Immunotherapy targeting PD-1 and/or CTLA4 can lead to durable responses in some melanoma patients. However, treatment resistance and lack of response are common. This study identifies a vulnerability in melanoma driven by immune cell activity, providing potential strategies for combination therapies.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Oncology
Xiaowei Fu, Xueqiang Deng, Weidong Xiao, Bo Huang, Xuan Yi, Yeqing Zou
Summary: The study showed that downregulation of NEAT1 sensitized gemcitabine-resistant pancreatic cancer cells by mediating the expression of ZEB2 through sponging miR-506-3p. NEAT1 downregulation reversed the EMT process in pancreatic cancer cells, enhancing their sensitivity to gemcitabine. These findings provide novel insights into the function and molecular mechanism of NEAT1 and offer a new approach to improving chemotherapy effectiveness in pancreatic cancer.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Ella Rimmer, Sadaf Rashid, Igor Kraev, Francesc Miralles, Androulla Elia
Summary: Pancreatic cancer cells release extracellular vesicles that confer resistance to gemcitabine and TRAIL treatment. Removal of these vesicles during treatment may improve the response of pancreatic cancer cells to gemcitabine and TRAIL.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Bin Xie, JunQi Yang, Jun Zhang
Summary: This study investigated the combined effect of chrysin, an apigenin analog with high therapeutic potential, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on Saos-2 and MG-63 cells. The results showed that chrysin synergistically increased the cytotoxic effects of TRAIL and sensitized the cells to TRAIL-induced apoptosis by decreasing the expression levels of antiapoptotic genes. This suggests that chrysin can sensitize osteosarcoma cells to TRAIL through the death receptor pathway, and the combinational therapy of these agents may improve the clinical efficacy of TRAIL-induced apoptosis in patients with osteosarcoma.
CELL BIOLOGY INTERNATIONAL
(2022)
Article
Pharmacology & Pharmacy
Da Eun Lee, Hyeon Woong Kang, So Yi Kim, Myeong Jin Kim, Jae Woong Jeong, Woosol Chris Hong, Sungsoon Fang, Hyung Sun Kim, Yun Sun Lee, Hyo Jung Kim, Joon Seong Park
Summary: This study demonstrates that the combination of ivermectin and gemcitabine effectively suppresses pancreatic cancer by inhibiting cell proliferation and inducing cell apoptosis through cell cycle arrest and mitochondrial dysfunction. In vivo experiments also support the tumor-inhibiting effect of this combination treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Nagamani Vunnam, Malaney C. Young, Elly E. Liao, Chih Hung Lo, Evan Huber, MaryJane Been, David D. Thomas, Jonathan N. Sachs
Summary: Although nimesulide has been taken off the market due to hepatotoxicity, it is still used as a valuable research tool for developing new anticancer drugs. Several studies have been conducted to modify its structure and develop more potent anticancer agents. Understanding the mechanism of action for nimesulide is crucial in realizing its potential.
CANCER BIOLOGY & THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Nada Abdullah, Yahya Tamimi, Sergey Dobretsov, Najwa Al Balushi, Jalila Alshekaili, Hamed Al Balushi, Mahmood Al Kindi, Syed Imran Hassan, Shadia Al Bahlani, Benjamin K. Tsang, Ikram A. Burney
Summary: The marine-derived compound MalforminA1 exhibited cytotoxic activity on both cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines, with a synergistic effect observed when combined with cisplatin. This demonstrates promising potential for MalforminA1 in overcoming drug resistance in ovarian cancer cells. Additionally, down-regulation of bcl2 and p53 genes suggests that MalforminA1 may induce cell death through a non-canonical pathway.
Article
Gastroenterology & Hepatology
Prasad Dandawate, Gaurav Kaushik, Chandrayee Ghosh, David Standing, Afreen Asif Ali Sayed, Sonali Choudhury, Dharmalingam Subramaniam, Ann Manzardo, Tuhina Banerjee, Santimukul Santra, Prabhu Ramamoorthy, Merlin Butler, Subhash B. Padhye, Joaquina Baranda, Anup Kasi, Weijing Sun, Ossama Tawfik, Domenico Coppola, Mokenge Malafa, Shahid Umar, Michael J. Soares, Subhrajit Saha, Scott J. Weir, Animesh Dhar, Roy A. Jensen, Sufi Mary Thomas, Shrikant Anant
Article
Cell Biology
Dharmalingam Subramaniam, Pablo Angulo, Sivapriya Ponnurangam, Prasad Dandawate, Prabhu Ramamoorthy, Pugazhendhi Srinivasan, Tomoo Iwakuma, Scott J. Weir, Katherine Chastain, Shrikant Anant
CELL DEATH & DISEASE
(2020)
Article
Cell Biology
John M. Perry, Fang Tao, Anuradha Roy, Tara Lin, Xi C. He, Shiyuan Chen, Xiuling Lu, Jacqelyn Nemechek, Linhao Ruan, Xiazhen Yu, Debra Dukes, Andrea Moran, Jennifer Pace, Kealan Schroeder, Meng Zhao, Aparna Venkatraman, Pengxu Qian, Zhenrui Li, Mark Hembree, Ariel Paulson, Zhiquan He, Dong Xu, Thanh-Huyen Tran, Prashant Deshmukh, Chi Thanh Nguyen, Rajeswari M. Kasi, Robin Ryan, Melinda Broward, Sheng Ding, Erin Guest, Keith August, Alan S. Gamis, Andrew Godwin, G. Sitta Sittampalam, Scott J. Weir, Linheng Li
NATURE CELL BIOLOGY
(2020)
Article
Multidisciplinary Sciences
Li Ren Kong, Richard Weijie Ong, Tuan Zea TariD, Nur Afiqah Binte Mohamed Salleh, Matan Thangavelu, Jane Vin Chan, Lie Yong Judice Koh, Giridharan Periyasamy, Jieying Amelia Lau, Thi Bich Uyen Le, Lingzhi Wang, Miyoung Lee, Srinivasaraghavan Kannan, Chandra S. Verma, Chwee Ming Lim, Wee Joo Chng, David P. Lane, Ashok Venkitaraman, Huynh The Hung, Chit Fang Cheok, Boon Cher Goh
NATURE COMMUNICATIONS
(2020)
Review
Oncology
Connor Chestnut, Dharmalingam Subramaniam, Prasad Dandawate, Subhash Padhye, John Taylor, Scott Weir, Shrikant Anant
Summary: Bladder cancer is the 9th most prevalent cancer worldwide, with a protracted treatment course and significant patient expense. Current first-line treatments for non-muscle invasive bladder cancer have high rates of tumor recurrence and progression, highlighting the need for new and improved strategies. Natural phytochemicals are being investigated for their potential therapeutic effects on bladder cancer, targeting molecular signaling pathways involved in its pathogenesis.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
(2021)
Article
Medicine, General & Internal
Joo-Leng Low, Dawn Pingxi Lau, Xiaoqian Zhang, Xue-Lin Kwang, Neha Rohatgi, Jane Vin Chan, Fui-Teen Chong, Stephen Qi Rong Wong, Hui-Sun Leong, Matan Thangavelu Thangavelu, Shivaji Rikka, Anders Martin Jacobsen Skanderup, Daniel Shao Weng Tan, Giridharan Periyasamy, Judice Lie Yong Koh, N. Gopalakrishna Iyer, Ramanuj DasGupta
Summary: The study reveals that in the absence of activating EGFR mutations, HNSCC cells may develop resistance to gefitinib through decreased cell proliferation, making them highly vulnerable to cell-cycle inhibitors.
Article
Pharmacology & Pharmacy
Amlan Das, Inamul Haque, Priyanka Ray, Arnab Ghosh, Debasmita Dutta, Mohiuddin Quadir, Archana De, Sumedha Gunewardena, Indranil Chatterjee, Snigdha Banerjee, Scott Weir, Sushanta K. Banerjee
Summary: This study demonstrates that EGCG activates CCN5 to inhibit in vitro cell viability, reverse TNBC cells' stemness, and suppress tumor growth. Additionally, EGCG-loaded nanoparticles are found to be more effective in suppressing tumors compared to free-EGCG.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2021)
Article
Oncology
Olivia K. Provance, Eric S. Geanes, Asona J. Lui, Anuradha Roy, Sean M. Holloran, Sumedha Gunewardena, Christy R. Hagan, Scott Weir, Joan Lewis-Wambi
Summary: Overexpression of IFITM1 in TNBC promotes tumor progression, but targeting IFITM1 can inhibit cell proliferation and invasion through the NF-kappa B signaling pathway. Parthenolide, identified as an NF kappa B inhibitor, shows potential as a cytotoxic agent for TNBC treatment.
Article
Cell Biology
Scott J. Weir, Prasad Dandawate, David Standing, Sangita Bhattacharyya, Prabhu Ramamoorthy, Parthasarathy Rangarajan, Robyn Wood, Amanda E. Brinker, Benjamin L. Woolbright, Mehmet Tanol, Tammy Ham, William McCulloch, Michael Dalton, Gregory A. Reed, Michael J. Baltezor, Roy A. Jensen, John A. Taylor, Shrikant Anant
Summary: CPX-POM shows anti-proliferative and anti-clonogenic effects on high-grade urothelial cancer by inhibiting the Notch signaling pathway. In a mouse bladder cancer model, CPX-POM treatment significantly reduces tumor volume and lowers the stage of bladder cancer, accompanied by a decrease in the proliferation index.
CELL DEATH & DISEASE
(2021)
Article
Cell Biology
Dharmalingam Subramaniam, Sivapriya Ponnurangam, Satish Ramalingam, Deep Kwatra, Prasad Dandawate, Scott J. Weir, Shahid Umar, Roy A. Jensen, Shrikant Anant
Summary: Honokiol (HNK) inhibits proliferation and colony formation, induces apoptosis, and suppresses colonosphere formation in colon cancer cells. HNK interacts with DCLK1, suppresses its kinase activity, and inhibits the expression of cancer stem cell marker proteins such as LGR5 and CD44. Additionally, HNK prevents colon tumorigenesis by inducing PUMA-YAP1 interaction and cytoplasmic sequestration, thereby suppressing oncogenic YAP1 activity.
Article
Multidisciplinary Sciences
Raghuvaran Shanmugam, Mert Burak Ozturk, Joo-Leng Low, Semih Can Akincilar, Joelle Yi Heng Chua, Matan Thangavelu Thangavelu, Giridharan Periyasamy, Ramanuj DasGupta, Vinay Tergaonkar
Summary: Understanding the regulatory mechanisms of mutant hTERT promoters can lead to the identification of potential therapeutic targets for specifically blocking telomerase reactivation in cancer cells.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Rachel L. Y. Wong, Megan R. E. Wong, Chik Hong Kuick, Seyed Ehsan Saffari, Meng Kang Wong, Sheng Hui Tan, Khurshid Merchant, Kenneth T. E. Chang, Matan Thangavelu, Giridharan Periyasamy, Zhi Xiong Chen, Prasad Iyer, Enrica E. K. Tan, Shui Yen Soh, N. Gopalakrishna Iyer, Qiao Fan, Amos H. P. Loh
Summary: Neuroblastoma is characterized by few recurrent single nucleotide variations (SNVs) but frequent and heterogeneous copy number variations (CNVs), with in-vitro cytotoxicity significantly correlated with CNVs rather than SNVs. Copy number gains of PI3K and STAT family genes on 17q were particularly associated with susceptibility to PI3K and cell cycle agents, providing potential guidance for personalized therapy in neuroblastoma.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Wei Xiang, Yi Hui Lam, Giridharan Periyasamy, Charles Chuah
Summary: Acute myeloid leukemia (AML) is a complex hematological malignancy with extensive heterogeneity, making it a prototype for personalized medicine. Recent studies have shown the potential of implementing genomic and phenotypic screens to improve survival in refractory AML patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Elizabeth Gonzalez, Atif A. Ahmed, Laura McCarthy, Katherine Chastain, Sahibu Habeebu, Marta Zapata-Tarres, Rocio Cardenas-Cardos, Liliana Velasco-Hidalgo, Celso Corcuera-Delgado, Rodolfo Rodriguez-Jurado, Lilia Garcia-Rodriguez, Alejandro Parrales, Tomoo Iwakuma, Midhat S. Farooqi, Brian Lee, Scott J. Weir, Terrie G. Flatt
Summary: This study demonstrates that the perinucleolar compartment (PNC) is prevalent in metastatic tumors and is associated with a distinct microRNA profile and shorter disease-free survival. PNC prevalence is higher in Hispanic patients and may contribute to the ethnic disparity in this tumor.
Article
Cell & Tissue Engineering
Rupal P. Soder, Buddhadeb Dawn, Mark L. Weiss, Neil Dunavin, Scott Weir, James Mitchell, Meizhang Li, Leyla Shune, Anurag K. Singh, Siddhartha Ganguly, Marc Morrison, Haitham Abdelhakim, Andrew K. Godwin, Sunil Abhyankar, Joseph McGuirk
STEM CELL REVIEWS AND REPORTS
(2020)